Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Conversions of leukemia cell lineage are rare, but occur most commonly in the setting of MLL‐rearrangement. Blinatumomab is a bidirection...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2016-06, Vol.63 (6), p.1113-1115
Hauptverfasser:	Rayes, Ahmad, McMasters, Richard L., O'Brien, Maureen M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Bispecific - therapeutic use Antigens, CD19 Antineoplastic Combined Chemotherapy Protocols - therapeutic use blinatumomab CD19 Cell Lineage - drug effects Chemotherapy Gene Rearrangement Hematology Humans Infant Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology lineage Male MLL Myeloid-Lymphoid Leukemia Protein - genetics Oncology Pediatrics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Conversions of leukemia cell lineage are rare, but occur most commonly in the setting of MLL‐rearrangement. Blinatumomab is a bidirectional antibody targeting CD19 with significant activity in relapsed B‐precursor ALL. We report an infant with ALL with t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated with blinatumomab. Following rapid initial clearance of peripheral lymphoblasts, bone marrow evaluation demonstrated a leukemic lineage switch to CD19‐negative monoblastic AML. Complete remission was achieved with myeloid‐directed chemotherapy.
ISSN:	1545-5009 1545-5017
DOI:	10.1002/pbc.25953